Table I.
Expression of TACSTD2 in salivary adenoid cystic carcinoma and its association with clinicopathological variables.
| TACSTD2 expression | ||||||
|---|---|---|---|---|---|---|
|
|
||||||
| n | N, n (%) | W, n (%) | M, n (%) | S, n (%) | P-value | |
| Gender | 81 | 18 (22.2) | 27 (33.3) | 20 (24.7) | 16 (19.7) | 0.582a |
| Male | 37 | 10 (27.0) | 11 (29.7) | 9 (24.3) | 7 (18.9) | |
| Female | 44 | 8 (18.2) | 16 (36.4) | 11 (25.0) | 9 (20.5) | |
| Age (years) | 0.328a | |||||
| ≤50 | 46 | 12 (26.1) | 16 (34.8) | 9 (19.6) | 9 (19.6) | |
| >50 | 35 | 6 (17.1) | 11 (31.4) | 11 (31.4) | 7 (19.8) | |
| Histological subtype | 0.289b | |||||
| Tubular | 32 | 6 (18.8) | 14 (43.8) | 7 (21.9) | 5 (15.6) | |
| Cribriform | 28 | 9 (32.1) | 8 (28.6) | 5 (17.9) | 6 (21.4) | |
| Solid | 21 | 3 (14.3) | 5 (23.8) | 8 (38.1) | 5 (23.8) | |
| TNM Stage | 0.020a | |||||
| I+II | 32 | 13 (40.6) | 8 (25.0) | 6 (18.8) | 5 (15.6) | |
| III+IV | 49 | 5 (10.2) | 19 (38.8) | 14 (28.6) | 11 (22.4) | |
| Perineural invasion | 0.053a | |||||
| Negative | 41 | 13 (34.2) | 11 (28.9) | 8 (21.1) | 6 (15.8) | |
| Positive | 40 | 5 (11.6) | 16 (37.2) | 12 (27.9) | 10 (23.3) | |
| Local recurrence | 0.002a | |||||
| Negative | 35 | 12 (34.3) | 14 (40.0) | 6 (17.1) | 3 (8.6) | |
| Positive | 46 | 6 (13.0) | 13 (28.3) | 14 (30.4) | 13 (28.3) | |
| Distant metastasis | 0.001a | |||||
| Negative | 52 | 15 (28.8) | 20 (38.5) | 12 (23.1) | 5 (9.6) | |
| Positive | 29 | 3 (10.3) | 7 (24.1) | 8 (27.6) | 11 (37.9) | |
TACSTD2 expression was scored according to the percentage of positive tumor cells and the intensity of staining. N, negative; W, weakly positive; M, moderately positive; S, strongly positive.
a
Mann-Whitney and
b
Kruskal-Wallis test.
TACSTD2, tumor-associated calcium signal transducer 2.